Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Exploratory endpoints included achieving 15% and 20% weight loss, and patient-reported outcomes assessed using the SF-36 v2.0 and the Three-Factor Eating Questionnaire (TFEQ-R18 v2)
Discovery of BMS-986339, a pharmacologically differentiated farnesoid X receptor agonist for the treatment of nonalcoholic steatohepatitis
It helps make myelin, a fatty substance that protects nerves
Talk to your doctor about glutathione to determine if its right for you
Promotes Normal Detoxification*
Benefits Preclinical data
US$ 29.90
US$ 24.04
US$ 21.61
US$ 24.90
